

30 June 2025

Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

Resolution	For*		Against		Votes withheld
	Total votes	%	Total votes	%	
1. To receive the Company's annual report and accounts for the year ended 31 December 2024	113,796,829	100.00	0	0.00	0
2. To approve the Directors' Remuneration Policy	113,434,973	99.68	359,286	0.32	2,570
3. To approve the 2024 Remuneration Report	113,529,139	99.77	265,120	0.23	2,570
4. To re-appoint Edwin Matthew Bower as a Director of the Company	113,762,519	99.97	34,200	0.03	110
5. To re-appoint Allan John Syns as a Director of the Company	113,762,519	100.00	0	0.00	34,310
6. To re-appoint PKF Littlejohn LLP as auditor of the Company	113,696,829	99.91	100,000	0.09	0
7. To authorise the Directors to determine the auditor's remuneration	113,796,709	100.00	110	0.00	10
8. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company	113,796,719	100.00	110	0.00	0
9. Authorise the Directors to allot equity securities	112,297,509	98.68	1,499,310	1.32	10

disapplying pre-emption rights					
10. That General Meetings may be called on not less than 14 days' notice	113,796,829	100.00	0	0.00	0

Notes:

***"Votes For" include votes giving the Chairman's discretion.**

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale / Piers Shimwell (Corporate Finance)
Anrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

IFC Advisory Limited
Tim Metcalfe
Florence Staton

+44(0) 20 3934 6630

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSDIFESEISELM